|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61K 39/3955 | (2013.01) | ||
| A61K 31/407 | (2006.01) | ||
| A61K 31/495 | (2013.01) | ||
| A61K 31/495 | (2006.01) | ||
| C07K 16/22 | (2013.01) | ||
| C07K 16/2896 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/02 | (2006.01) | ||
| C07K2317/21 | (2013.01) | ||
| C07K2317/24 | (2013.01) | ||
| C07K2317/73 | (2013.01) | ||
| A61K 31/407 | (2013.01) | ||
| A61K2039/545 | (2013.01) | ||
| A61N2005/1098 | (2013.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) |
| (11) | Number of the document | 3463458 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17730628.9 |
| Date of filing the European patent application | 2017-06-01 | |
| (97) | Date of publication of the European application | 2019-04-10 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/035504 |
| Date | 2017-06-01 |
| (87) | Number | WO 2017/210463 |
| Date | 2017-12-07 |
| (30) | Number | Date | Country code |
| 201662344194 P | 2016-06-01 | US | |
| 201662349491 P | 2016-06-13 | US | |
| 201662362845 P | 2016-07-15 | US | |
| 201662374136 P | 2016-08-12 | US | |
| 201662418466 P | 2016-11-07 | US | |
| 201662424178 P | 2016-11-18 | US | |
| 201762471321 P | 2017-03-14 | US | |
| 201762490528 P | 2017-04-26 | US | |
| 201762491943 P | 2017-04-28 | US |
| (72) |
TRIKHA, Mohit , US
LEVIN, Nancy , US
MACLAREN, Ann , US
|
| (73) |
Celgene Tri A Holdings Ltd. ,
Aon House 30 Woodbourne Avenue, Pembroke HM 08,
BM
Trikha, Mohit , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US Levin, Nancy , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US Maclaren, Ann , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US |
| (54) | COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS |
| COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS |